Your browser doesn't support javascript.
Mavrilimumab for severe COVID-19 - Authors' reply.
De Luca, Giacomo; Cavalli, Giulio; Campochiaro, Corrado; Della-Torre, Emanuel; Dagna, Lorenzo.
  • De Luca G; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Cavalli G; Vita-Salute San Raffaele University, Milan, Italy.
  • Campochiaro C; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Della-Torre E; Vita-Salute San Raffaele University, Milan, Italy.
  • Dagna L; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Lancet Rheumatol ; 2(11): e662-e663, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-748133
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Lancet Rheumatol Year: 2020 Document Type: Article Affiliation country: S2665-9913(20)30308-8

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Lancet Rheumatol Year: 2020 Document Type: Article Affiliation country: S2665-9913(20)30308-8